When treating refractory kidney cancer, clinicians prioritize regimens offering the most durable initial response. They argue against “saving” effective drugs for later, as disease progression is traumatic for patients and many never successfully receive subsequent lines of therapy. The goal is long-term disease control now, not preserving theoretical future options.

The emergence of positive data from trials like PATINA creates a dilemma for oncologists treating patients who are already stable on an older maintenance therapy. The consensus suggests not altering a successful regimen to avoid disrupting patient stability, revealing a cautious approach to integrating new evidence into established care.

The standard practice of a 6-8 cycle chemotherapy induction followed by maintenance wasn't a deliberate trial design. It evolved organically from patient intolerance to cumulative toxicities like neuropathy, a limitation newer, less toxic drugs like TDXD don't necessarily share.

When introducing the overall, multi-year treatment plan at the beginning, it helps patients conceptualize myeloma as a chronic condition rather than a series of acute failures. This reframing prepares them for eventual relapse, reducing devastation and helping them see it as the next step in a long journey.

The IMFORTE trial saw a 25% attrition rate between induction and randomization for maintenance therapy. This reflects the clinical reality that a significant portion of patients are too debilitated by initial chemo-IO to be candidates for intensified maintenance, making immunotherapy alone a reasonable alternative for them.

Beyond rigid trial protocols, a flexible approach to first-line T-DXd is practical and patient-centered. This includes discussing treatment breaks for holidays or switching to a less burdensome maintenance regimen (like subcutaneous HP) if a patient is tired of frequent clinic visits, prioritizing their quality of life.

To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.

The arrival of multiple effective ADCs and targeted therapies means clinicians can no longer just focus on the next best treatment. They must think "five plays ahead," strategically sequencing therapies to maximize longevity. Today's treatment choice is now heavily influenced by the need to preserve future options.

Since the IMFORTE trial excluded patients with brain metastases, oncologists hold differing views. Some are purists and avoid it off-protocol, while others explain the lack of evidence (which isn't negative evidence) to the patient and consider it, especially if CNS disease is controlled, creating a personalized decision-making scenario.